Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2024Neurology

10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)

View Full Paper
Ask AI
Bookmark
Share

Authors

SHStephen L. HauserLKLudwig KapposMFMassimo Filippi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hauser et al. (2024) studied this question.

synapsesocial.com/papers/68e6fca8b6db643587676877https://doi.org/10.1212/wnl.0000000000205584
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis2025
  2. 2Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers2024 · 13 citations
  3. 3Real-world Data on Ocrelizumab Treatment: Efficacy, Safety, and Tolerability Analysis in Patients with Relapsing Remitting and Primary Progressive Multiple Sclerosis in Southeastern Ontario (P2-6.014)2024
  4. 4Systematic review on Ocrevus for treatment of multiple sclerosis2024 · 1 citations
  5. 5A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year2026